Article
Glycosylation in Biologic CMC — N-Glycan Profiling, Afucosylation, ADCC
The glycan profile of a monoclonal antibody is not just a quality attribute — it is a pharmacological variable. Afucosylation directly affects ADCC effector function. High mannose content…
XGene Articles & Analysis
Evidence-led analysis for decisions that matter.
Senior-authored regulatory, CMC, GMP, quality, and inspection analysis designed for practical use—not passive reading.
01SignalSource evidence
02InterpretTechnical judgment
03ApplyDecision pathway
Publication library
Keep moving from evidence to decision.
Article
Glycosylation in Biologic CMC — N-Glycan Profiling, Afucosylation, ADCC
The glycan profile of a monoclonal antibody is not just a quality attribute — it is a pharmacological variable. Afucosylation directly affects ADCC effector function. High mannose content…
Article
Digital Twin in Pharma Manufacturing — CMC Implications of the Virtual Batch
Pharmaceutical companies are investing in digital twin technology for manufacturing process simulation — and most of them are discovering that the regulatory framework for using digital twin outputs…
Article
ADC CMC — DAR Distribution, Linker-Payload Impurities, and the BLA Package
An antibody drug conjugate is simultaneously a biologic (the antibody component) and a small molecule drug (the cytotoxic payload) joined by a linker chemistry. FDA and EMA regulate…
Article
MVDA and Continued Process Verification — Stage 3 PV with Multivariate Models
Univariate control charts monitoring individual CPPs and CQAs will detect many process failures — but multivariate statistical models that simultaneously monitor the relationships between parameters will detect the…
Article
Biosimilar CMC Strategy — 351(k) Pathway and Analytical Similarity Tiers
"The analytical similarity assessment does not include a finger-printing approach to structural characterization — the submitted data compare only the attributes in the proposed biosimilar specification against the…
Article
Raman Spectroscopy as PAT — CMC Validation and Regulatory Submission
Raman spectroscopy has become one of the most versatile Process Analytical Technology tools in pharmaceutical manufacturing — applied to blend uniformity, raw material identification, in-line polymorph monitoring, and…
Article
Comparability — ICH Q5E and the Manufacturing Change Evidence Package
"The comparability study data provided do not demonstrate that the pre- and post-change drug substance lots are comparable with respect to potency and glycosylation profile — the analytical…
Article
EMA CHMP CMC Guideline Update — Harmonization and Practical Impact
"EMA's scientific thinking on biologics development for rare diseases introduces CMC accommodations that are not available under the standard biologics development framework — and companies developing orphan biologics…
Article
Biologic Drug Product Control and Release — The Specification Architecture
The drug product specification for a biologic is not a downward extension of the drug substance specification. It includes all drug substance quality attributes at their post-formulation and…
Article
NIR Spectroscopy and Real-Time Release Testing — The CMC Evidence Package
Near-infrared spectroscopy as a Process Analytical Technology for real-time release testing is one of the most powerful tools available for pharmaceutical manufacturing — and one of the most…
Article
Biologic Drug Product Manufacture — Aseptic Processing and Fill-Finish CMC
Aseptic manufacturing of biologic drug products operates at the intersection of GMP facility requirements (EU Annex 1 2022, FDA Aseptic Processing Guidance 2004) and BLA manufacturing process description…
Article
AI for GMP Lab Anomaly Detection — What the Technology Actually Does
AI-powered anomaly detection for GMP laboratories is being sold by technology vendors with claims that significantly exceed what the technology can currently deliver in a GMP-validated context —…
Read with purpose
Every analysis should make the next move clearer.
- 01ReadUnderstand the technical argument.
- 02TraceFollow evidence and regulatory context.
- 03CompareExplore related XGene intelligence.
- 04ActConnect the issue to a practical pathway.